in neonatal Staphylococci septicaemia. Moreover, this AUC 24 /MIC target level of 400 is based on total vancomycin concentration, while Smits et al recently demonstrated that the fraction unbound (FU) of vancomycin is much higher in neonates (median 0.9) compared with that in adults (median 0.6). 5 Using PK/PD simulation, we have explored the impact of this recent finding on vancomycin dosing in neonates.
It is important to first introduce two different concepts for vancomycin dosing optimization in neonates.
• The traditional "total drug target approach" aimed at achieving similar total vancomycin exposure in neonates as in adults, irrespective of the differences in protein binding, and thus targeted an AUC 24 / MIC ≥ 400 for optimal dosing in neonates.
• A novel "unbound drug target approach," based on the recent find- Vancomycin PK parameters and exposure profiles of these 249
neonates were estimated using a PK model which was previously developed during a population PK meta-analysis of vancomycin in neonates. 7 Briefly, this two-compartment model was built based on a dataset of 4894 vancomycin concentrations from 1631 neonates.
In this PK model, bodyweight, post-menstrual age (PMA), and serum creatinine value were the significant covariates for clearance.
In the selected cohort, population PK parameters (mean ± SD)
obtained from this PK model were Vd (sum of V1 and 
